Literature DB >> 2912723

The binding of double-stranded RNA and adenovirus VAI RNA to the interferon-induced protein kinase.

J Galabru1, M G Katze, N Robert, A G Hovanessian.   

Abstract

The protein kinase from human cells dependent on double-stranded (ds) RNA is a 68-kDa protein (p68 kinase), the level of which is enhanced significantly in cells treated with interferon. When activated by low concentrations of dsRNA, the p68 kinase becomes phosphorylated and thereby catalyzes the phosphorylation of the protein-synthesis initiation factor, eIF2. Here, we have purified the p68 kinase to homogeneity using a specific monoclonal antibody to investigate its capacity to bind dsRNA, poly(I).poly(C). Our study suggest that p68 kinase has high- and low-affinity binding sites: the high-affinity binding site is responsible for the activation and the low-affinity binding site for the inhibition of kinase activity. This is in accord with the fact that autophosphorylation of p68 kinase occurs at low concentrations of dsRNA whereas high concentrations of dsRNA inhibit its autophosphorylation. We have also investigated the binding of adenoviral VAI RNA to the purified p68 kinase and have found that the affinity of this binding is lower than that of poly(I).poly(C). We show that VAI RNA can activate or inhibit autophosphorylation of p68 kinase in a dose-dependent manner, i.e. activation at less than or equal to 1 microgram/ml or inhibition at greater than 1 microgram/ml of VAI RNA. In spite of its lower affinity of binding, VAI RNA cannot be displaced by poly(I).poly(C) or reovirus dsRNA. These data confirm our previous results to illustrate that VAI RNA can bind p68 kinase and cause its inactivation irreversably.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912723     DOI: 10.1111/j.1432-1033.1989.tb14485.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  51 in total

1.  Sensitivity of an epstein-barr virus-positive tumor line, Daudi, to alpha interferon correlates with expression of a GC-rich viral transcript.

Authors:  Y Gao; S a Xue; B E Griffin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 2.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

3.  A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR.

Authors:  S Nanduri; F Rahman; B R Williams; J Qin
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

4.  Phosphorylation of the RNA-dependent protein kinase regulates its RNA-binding activity.

Authors:  N V Jammi; P A Beal
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

5.  Analysis of PKR activation using analytical ultracentrifugation.

Authors:  James L Cole
Journal:  Macromol Biosci       Date:  2010-07-07       Impact factor: 4.979

6.  Targeting a KH-domain protein with RNA decoys.

Authors:  Aleksandr V Makeyev; Dawn L Eastmond; Stephen A Liebhaber
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

7.  Interactions between double-stranded RNA regulators and the protein kinase DAI.

Authors:  L Manche; S R Green; C Schmedt; M B Mathews
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

8.  Removal of double-stranded contaminants from RNA transcripts: synthesis of adenovirus VA RNAI from a T7 vector.

Authors:  K H Mellits; T Pe'ery; L Manche; H D Robertson; M B Mathews
Journal:  Nucleic Acids Res       Date:  1990-09-25       Impact factor: 16.971

9.  Unactivated PKR exists in an open conformation capable of binding nucleotides.

Authors:  Peter A Lemaire; Ingrid Tessmer; Ranyelle Craig; Dorothy A Erie; James L Cole
Journal:  Biochemistry       Date:  2006-08-01       Impact factor: 3.162

10.  Mechanism of interferon action: characterization of the intermolecular autophosphorylation of PKR, the interferon-inducible, RNA-dependent protein kinase.

Authors:  D C Thomis; C E Samuel
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.